BOSTON , Jan. 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE ), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that Christian S.

The trial failed to meet its primary endpoint of complete remission (CR) rate CR rate was 53% higher in eprenetapopt with AZA arm compared to AZA alone, but did not reach statistical significance BOSTON , Dec. 28, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc.

BOSTON , Nov. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that the U.S.

BOSTON , Nov. 19, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that Christian S.

BOSTON , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three and nine

BOSTON , Oct. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant tumor suppressor protein, p53, will host a live virtual R&D Day Webinar, with presentations by

BOSTON , Oct. 14, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant tumor suppressor protein, p53, today announced the launch of p53reactivation.com .

BOSTON , Oct. 07, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc. , (NASDAQ: APRE ), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced that the U.S.

BOSTON , Sept. 29, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc. , (NASDAQ: APRE ), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced the appointment of Michael A.

BOSTON , Sept. 18, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc. , (NASDAQ: APRE ), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced the promotion of Gregory S.